➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Colorcon
Dow
Merck
AstraZeneca

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

Litigation Details for IDERA PHARMACEUTICALS, INC. v. KAPPOS (D.C. 2010)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Biologic Drugs cited in IDERA PHARMACEUTICALS, INC. v. KAPPOS

The biologic drugs covered by the patent cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for IDERA PHARMACEUTICALS, INC. v. KAPPOS (D.C. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-01-29 1 Complaint the assignee of United States Patent No. 7,569,554 (“the ‘554 Patent,” attached as Exhibit A), pursuant… that the patent term adjustment for the ‘554 Patent be 606 days, whereby the ‘554 Patent will expire…‘554 Patent, which is May 14, 2004, and the correct patent term expiration of the ‘862 Patent, which … adjusted patent term of the ‘862 Patent expires on January 10, 2026 (the unextended patent term expiration…period of patent term adjustment for the ‘554 Patent term to 606 days, whereby the ‘554 Patent expires External link to document
2010-07-14 12 issued as U.S. Patent No. 7,569,554. Defendant denies that U.S. Patent No. 7,569,554 issued on June …June 9, 2009. Defendant avers that U.S. Patent No. 7,569,554 issued on August 4, 2009. Defendant admits …admits that the ‘554 Patent is subject to a terminal disclaimer over the ‘862 patent. Defendant admits …). Defendant denies that the patent term adjustment for the ‘554 Patent is determined in part with respect… the ‘862 Patent in order to fully determine the proper term adjustment of the ‘554 Patent. External link to document
2010-02-04 3 Amended Complaint by the assignee ofUnited States Patent No. 7,569,554 (“the ‘554 Patent,” attached as Exhibit A), pursuant…Page 2 of 10 patent term adjustment for the ‘554 Patent be 606 days, Whereby the ‘554 Patent Will expire…862 Patent expires on January 10, 2026. Accordingly, the patent term adjustment of the ‘554 Patent should…unextended patent term expiration of the ‘554 Patent, which is May 14, 2004, and the correct patent term expiration… adjusted patent term of the ‘862 Patent expires on January 10, 2026 (the unextended patent term expiration External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Baxter
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.